Precigen (PGEN)
(Delayed Data from NSDQ)
$0.90 USD
+0.06 (7.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.90 0.00 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.90 USD
+0.06 (7.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.90 0.00 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 5.08% and 39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Precigen, Inc. (PGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
by Zacks Equity Research
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.
Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of 11.11% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
3 Synthetic Biology Stocks in Focus With Strong Potential
by Indrajit Bandyopadhyay
Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.
Is the Options Market Predicting a Spike in Precigen (PGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Precigen (PGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.
Precigen, Inc. (PGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 16.67% and 49.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and 23.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Precigen, Inc. (PGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and -16.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Precigen, Inc. (PGEN) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Precigen (PGEN) Looks Good: Stock Adds 7.1% in Session
by Zacks Equity Research
Precigen (PGEN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Implied Volatility Surging for Precigen (PGEN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.
Precigen (PGEN) Soars: Stock Adds 9.4% in Session
by Zacks Equity Research
Precigen (PGEN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Should You Buy Precigen (PGEN) Ahead of Earnings?
by Zacks Equity Research
Precigen (PGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.